Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of RMB 23.23 [6][5]. Core Views - The company achieved a revenue of RMB 3.398 billion in 2025, representing a year-on-year growth of 10.7%, and a net profit attributable to the parent company of RMB 401 million, up 33.18% year-on-year [1][2]. - The company is optimistic about the future development of its microbial protein project and pet segment, which are expected to provide new growth momentum for high-quality development [1][5]. Revenue Breakdown - The revenue from the biological products segment was RMB 1.475 billion, growing by 11.4% year-on-year, accounting for 43.4% of total revenue [2]. - The pet segment saw significant growth, with revenue reaching RMB 858 million, a year-on-year increase of 24.4% [2]. - The international business segment reported revenue of RMB 127 million, with a year-on-year growth of 33.0% [2]. Profitability Analysis - The gross margin for the biological products business improved by 0.94 percentage points to 63.7%, enhancing overall profitability [3]. - The gross margin for the drug formulation and raw materials segment decreased by 1.34 percentage points to 35.3% due to intensified industry competition [3]. - The company increased its R&D investment, with R&D expenses reaching RMB 253 million, a year-on-year increase of 28.7% [3]. Strategic Initiatives - The company invested RMB 679 million to build a 60,000-ton annual production base for mycelium protein in Tianjin, which is expected to contribute approximately RMB 1.3 billion in annual revenue once fully operational [4]. - The company has obtained 19 new veterinary drug certificates in the pet sector, covering various fields such as deworming and vaccines, and has established a comprehensive supply chain covering over 14,000 medical terminals across 24 provinces [4].

Core Viewpoint - Beijing Shougang Longze Technology Co., Ltd. (Shougang Longze) is focused on the carbon capture, utilization, and storage (CCUS) industry, aiming to produce low-carbon products such as ethanol and microbial protein through innovative technologies [4]. Company Progress - Shougang Longze submitted its listing application to the Hong Kong Stock Exchange on March 27, 2024, with Yuexiu Finance as the exclusive sponsor [2]. - The company has successfully operated four large-scale production facilities in China, demonstrating the replicability of its proprietary technology [4]. - Shougang Longze has completed multiple rounds of financing since its establishment in 2011, with Shougang Group being the largest shareholder at 26.54% [4]. Business Model - The business model includes product sales (mainly ethanol and microbial protein) and providing comprehensive low-carbon solutions to industrial clients [5]. - The primary raw materials for production are carbon-containing industrial waste gases generated from steel and ferroalloy production processes [5]. - The company has commercialized first-generation decarbonization technology utilizing carbon monoxide and is developing second-generation negative carbon technology [5]. Financial Performance - Revenue projections for Shougang Longze are approximately 593 million RMB for 2023, 564 million RMB for 2024, and 522 million RMB for 2025 [6]. - The company is expected to incur losses of about 110 million RMB in 2023, 246 million RMB in 2024, and 325 million RMB in 2025 [6]. Industry Trends - The development of CCUS projects in China is rapidly increasing, with 16 new projects added in 2021 and expected to reach 20 by 2025, driven by government support [7]. - There is a growing willingness among enterprises to invest in CCUS projects to reduce carbon emissions, indicating a strong growth trend for the CCUS industry in the coming years [9].

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 北京首鋼朗澤科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）╱證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。您閱覽本文件，即代表您知悉、 接納並向本公司、其獨家保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據呈交香港公司註冊處處長註冊的本公 司招股章程作出投資決定；有關文本將於發售期內向公眾刊發。 (i) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本文件中 的資料作出任何投資決定； (ii) 在聯交所網站登載本文件或其補充、修訂或更換附頁，並不引起本公司、其獨家保薦人、整體協調 人、顧問或包銷團成員須在 ...

This Application Proof is in draft form. The information contained in it is incomplete and is subject to change which can be material. By viewing this document, you acknowledge, accept and agree with the Company, its sole sponsor, overall coordinator, advisers or members of the underwriting syndicate that: (the "Company") (A joint stock company incorporated in the People's Republic of China with limited liability) WARNING The publication of this Application Proof is required by The Stock Exchange of Hong Ko ...

Core Viewpoint - The article highlights the successful trial run of a new protein production platform by Beijing Deliangyuan Biotechnology Co., which marks a significant step towards full-scale production in the microbial protein industry [2][4]. Group 1: Company Developments - Beijing Deliangyuan has initiated a trial run of its 2T primary seed tank at its new protein production platform in Weiyuan County, Sichuan, achieving a successful first feed and fermentation process [2]. - The trial run adhered to preset processes without major anomalies, demonstrating excellent fermentation effects and achieving key performance indicators [4]. - The company plans to leverage the success of this trial to enhance process control and standardize fermentation operations, aiming for successful trials of 8T and 50T fermentation facilities in March [4]. Group 2: Future Focus and Innovations - Deliangyuan will continue to focus on technological innovation, optimizing fermentation processes, iterating strain performance, and upgrading intelligent production systems [4]. - The company aims to overcome technical bottlenecks and drive cost reduction and efficiency improvements in the microbial protein industry, contributing to high-quality development in the bio-manufacturing sector [4]. Group 3: Upcoming Events - The 11th Bio-based Industry Conference & Exhibition is scheduled for May 20-22, 2026, in Shanghai, aimed at fostering collaboration and promoting green low-carbon transformation in the industry [5][7]. - The event will feature 11 major forums covering various topics in the bio-based industry and 7 concurrent activities, including product exhibitions and strategic discussions [6][7].

Core Viewpoint - The article discusses the recent policies released by the Heilongjiang Provincial Government to support the high-quality development of the biomanufacturing industry, focusing on enhancing technological innovation, promoting industrial expansion and quality improvement, supporting key areas, and increasing resource guarantees [2]. Group 1: Enhancing Technological Innovation - Support for the construction of innovation platforms in biomanufacturing, including collaboration with universities and research institutions [3]. - Financial support for key technology research projects in biomanufacturing, with provincial funding for approved projects [3]. - Encouragement for enterprises to increase R&D investment, with subsidies for qualifying investments over 500,000 yuan [3]. - Support for the establishment of pilot testing platforms, with potential subsidies based on performance evaluations [3]. - Promotion of technology transfer activities, providing funding for contracts over 1 million yuan [3]. Group 2: Promoting Industrial Expansion and Quality Improvement - Financial support for new biomanufacturing projects with fixed asset investments over 20 million yuan, offering up to 50 million yuan in subsidies [4]. - Assistance for equipment upgrades in biomanufacturing enterprises to enhance production efficiency [4]. - Support for digital transformation using AI and big data, with subsidies for recognized digital workshops and smart factories [4]. - Encouragement for leading biomanufacturing enterprises to form innovation alliances to enhance collaboration and market expansion [4]. Group 3: Supporting Key Areas of Development - Financial incentives for new drug and high-end medical device development, with support based on clinical trial phases [5]. - Encouragement for the development of new food products, with rewards for approved new food materials [5]. - Support for the development of high-value biochemicals, with financial rewards for significant sales achievements [5]. Group 4: Increasing Resource Guarantees - Support for the construction of biomanufacturing parks and infrastructure, with potential bond funding [6]. - Assurance of key resource guarantees for biomanufacturing projects, including energy and land use [6]. - Strengthening financial support for biomanufacturing enterprises, including assistance for listing and innovative financing products [6]. - Enhancement of intellectual property protection for biomanufacturing innovations [7]. Group 5: Strengthening Talent Development - Encouragement for universities to develop relevant programs and facilitate talent acquisition in biomanufacturing [7]. - Support for research personnel to engage in innovation and technology transfer activities [7].

Core Viewpoint - The article discusses the policies implemented by the Heilongjiang Provincial Government to support the high-quality development of the biomanufacturing industry, emphasizing the promotion of biochemicals and materials with high technological content and added value [2][5]. Group 1: Enhancing Technological Innovation Capabilities - Support for the construction of innovation platforms in biomanufacturing, encouraging collaboration between enterprises and research institutions [6]. - Financial support for key technology research projects in biomanufacturing, including innovative drugs and biochemicals [6]. - Incentives for enterprises to increase R&D investment, with subsidies based on the amount invested [6]. - Support for the establishment of pilot testing platforms to facilitate the connection between R&D and production [6]. - Encouragement of technology transfer activities, with financial assistance for contracts exceeding 1 million yuan [6]. Group 2: Promoting Industry Expansion and Quality Improvement - Financial support for new biomanufacturing projects with fixed asset investments of 20 million yuan or more, providing up to 5 million yuan in subsidies [7]. - Support for equipment upgrades in biomanufacturing enterprises to enhance production efficiency [7]. - Encouragement for enterprises to adopt digital technologies, with financial incentives for recognized digital workshops and smart factories [7]. - Promotion of industry collaboration through the establishment of innovation alliances and research institutes [7]. Group 3: Supporting Key Sector Development - Focus on strengthening the biopharmaceutical sector with financial support for new drugs and high-end medical devices at various clinical trial stages [8]. - Encouragement for the development of new food products, providing rewards for approved new food ingredients [8]. - Promotion of biochemicals, with incentives for products achieving significant sales [8]. Group 4: Increasing Resource Assurance - Support for the construction of biomanufacturing parks and infrastructure improvements [9]. - Assurance of key resources for biomanufacturing projects, including energy and land [10]. - Strengthening financial services for biomanufacturing enterprises, including support for listing and innovative financing products [10]. - Enhancement of intellectual property protection for biomanufacturing innovations [10]. - Development of talent in the biomanufacturing sector through educational initiatives and support for high-level talent recruitment [10].

Core Viewpoint - The Heilongjiang Provincial Government has issued a set of policy measures to support the high-quality development of the biomanufacturing industry, aiming to enhance technological innovation, promote industrial expansion, and ensure resource allocation to create competitive advantages and seize future development opportunities [2][7]. Group 1: Enhancing Technological Innovation - Support for the construction of innovation platforms in biomanufacturing through collaboration between enterprises and research institutions, with financial rewards for approved national and provincial platforms [3][8]. - Encouragement for tackling core technological challenges in biomanufacturing, with provincial financial support for approved key research projects [3][8]. - Incentives for enterprises to increase R&D investment, with subsidies for qualifying expenditures exceeding 500,000 yuan, matched by provincial and municipal funding [3][8]. - Support for the establishment of pilot testing and verification platforms, with potential subsidies of up to 1 million yuan based on performance evaluations [3][8]. - Promotion of technology transfer activities, providing funding for contracts exceeding 1 million yuan for technology purchases from research institutions [3][8]. Group 2: Promoting Industrial Expansion and Quality Improvement - Financial support for new biomanufacturing projects in key sectors, with subsidies of up to 5 million yuan for fixed asset investments of 20 million yuan or more [4][9]. - Assistance for equipment upgrades in biomanufacturing enterprises to enhance production efficiency and reduce costs [4][9]. - Support for digital transformation using AI, big data, and IoT technologies, with subsidies for recognized digital workshops and smart factories [4][9]. Group 3: Supporting Key Sector Development - Focus on strengthening the biopharmaceutical sector with financial support for clinical trials and production of new drugs and high-end medical devices, with potential rewards of up to 1.5 million yuan [4][9]. - Encouragement for the development of new food products, with one-time rewards for approved new food materials and additives [4][9]. - Promotion of biochemicals with high added value, providing rewards for significant sales achievements in new products [4][9]. Group 4: Resource Allocation and Financial Support - Support for the construction of biomanufacturing parks and infrastructure, with potential bond funding for qualifying projects [5][10]. - Inclusion of biomanufacturing enterprises in key resource allocation for utilities, ensuring priority in energy supply [5][10]. - Financial services support for biomanufacturing enterprises to facilitate listing and access to capital markets, including innovative loan products [5][10]. Group 5: Intellectual Property and Talent Development - Strengthening intellectual property protection for biomanufacturing innovations, with services to expedite patent applications [10][11]. - Encouragement for educational institutions to develop relevant programs and attract high-level talent to the biomanufacturing sector [10][11]. Implementation Timeline - The policy measures are effective from the date of issuance until December 31, 2028, with provisions for adjustments based on national and provincial policy changes [10].

Core Insights - The biomanufacturing sector is gaining momentum with strong policy support and technological advancements, positioning it as a key future industry in China [1][2] - The market size of China's biomanufacturing industry is projected to reach approximately 1.8 trillion yuan by 2030, with significant contributions from food additives and biopharmaceuticals [1][2] Industry Developments - The Ministry of Industry and Information Technology has reported that during the 14th Five-Year Plan, China's biomanufacturing industry is expected to expand steadily, reaching a total scale of 1.1 trillion yuan, with bioproducts accounting for over 70% of global production [1] - The focus of the 14th Five-Year Plan is on the industrialization of technology, emphasizing pilot testing, process scaling, and demonstration line construction [2] Company Initiatives - Ruipu Biotech is investing 680 million yuan in a large-scale microbial protein industrialization demonstration project, aiming for trial production by Q4 2026 [3] - Fuxiang Pharmaceutical is leveraging its expertise in high-end antibiotic fermentation to enhance its microbial protein project, focusing on domestic and international expansion [4] - Yikela Biotech is targeting high-value aquatic feed proteins through a collaboration with Fudan University, aiming to reduce reliance on imported fishmeal [5] Technological Advancements - Synthetic biology is identified as a core technology driving low-carbon production and increased labor productivity across various sectors, including healthcare and industrial manufacturing [2] - The integration of AI with synthetic biology is expected to shift the competitive landscape from single-point breakthroughs to platform-based competition, enhancing R&D efficiency [7] Market Trends - The most promising sub-sectors in biomanufacturing during the 14th Five-Year Plan include high-value biomanufactured products in healthcare, bio-based materials, and service-oriented platforms [6] - The industry is anticipated to experience differentiation and improved quality as companies focus on scalable processes, cost control, and clear downstream applications [2][6]

Core Insights - The biomanufacturing sector is gaining momentum with strong policy support and corporate initiatives, positioning it as a key future industry with significant growth potential [1][2][4] Industry Overview - The biomanufacturing industry in China is projected to reach a scale of 1.1 trillion yuan during the 14th Five-Year Plan, with a forecasted growth to nearly 1.8 trillion yuan by 2030 [1] - The industry is characterized by a focus on low-carbon production and increased labor productivity through synthetic biology technologies, which are applicable across various sectors including healthcare, energy, and environmental protection [2] Policy and Market Dynamics - The "14th Five-Year Plan" emphasizes the transition from laboratory technologies to marketable solutions, highlighting the importance of pilot testing, process scaling, and demonstration line construction [2][6] - The integration of technology, policy, and market forces is essential for driving explosive growth in specific sub-sectors of biomanufacturing [2][6] Corporate Initiatives - Companies like Ruipu Biotech and Fuxiang Pharmaceutical are actively investing in biomanufacturing, focusing on microbial protein production and leveraging existing fermentation technologies for scale [3][4] - Ruipu Biotech is set to launch a 680 million yuan microbial protein industrialization project by 2025, aiming for high-quality production capabilities [3] Emerging Trends - The focus on marine biotechnology and high-value functional proteins is becoming a significant direction for the development of the marine economy [4] - The integration of AI with synthetic biology is expected to shift the competitive landscape from isolated breakthroughs to platform-based competition, enhancing R&D efficiency [6] Future Growth Areas - High-value biomanufactured products in the pharmaceutical sector, bio-based materials, and service-oriented platforms are identified as the most promising sub-sectors during the "14th Five-Year Plan" [5][6] - Addressing industrial bottlenecks through a complete chain from basic research to industrial application is crucial for enhancing international competitiveness [7]